A lot of money flowed through the pharma and biotech M&A space in the third quarter of this year, and while deal volume was similar to the second quarter, the value of those acquisitions shot up, according to analysts at Informa Pharma’s Biomedtracker unit.
In its just-published Dealmaking Quarterly Statistics report for Q3 2021, Biomedtracker noted that biopharma M&A value totalled $48.6bn from 38...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?